S1 File -

Table A. Tamoxifen increases fasting glucose but improves glucose tolerance in mixed genetic background (F1 hybrid B6129SF1/J) mice. (a) Schematic indicating time course of treatment. Mice received daily oral gavage with tamoxifen (0.025, 0.1, 0.2, or 0.3mg/g body weight) or vehicle for 5 days. Mice were sequentially labeled with BrdU for two weeks each, starting immediately after tamoxifen treatment. (b, c) Body weight (b) and blood glucose (c) change from the start of treatment (day -5) to the end of the experiment (day 14). Random fed (d) and fasting (e) blood glucose levels at the end of the experiment. (f, g) Glucose tolerance tests (GTT) 5 days after the end of tamoxifen with glucose curves (f) and GTT area under curve (AUC) calculations (g). (h, i) Insulin tolerance tests (ITT) 14 days after tamoxifen with glucose curves (h) and ITT area under curve (AUC) calculations (i). Results expressed as mean ± SEM for 10 mice per group. **p≤0.01, ***p≤0.001, tamoxifen vs. vehicle.
Table B. Individual Beta Cell Morphemtry Data from Tamoxifen-Treated Mixed Genetic Background (F1 C57Bl6/129) Mice. Genetic background, mouse ID, pancreas mass (mg), β-cell area (%), β-cell mass (mg).
Table C. Individual Beta Cell TUNEL Data from Tamoxifen-Treated Mixed Genetic Background (F1 C57Bl6/129) Mice. Genetic background, mouse ID, β-cells, TUNEL+ DAPI+ Insulin- Islet Cells, TUNEL+ DAPI+ Insulin- Islet Cells (% of β-cells), TUNEL+ β-cells, TUNEL+ β-cells (% of β-cells).
Table D. Individual Beta Cell and Acinar Cell Proliferation from Tamoxifen-Treated Mixed Genetic Background (F1 C57Bl6/129) Mice. Mouse ID, β-cell (number), BrdU+ β-cells (number; % total), acinar cell (number), BrdU+ acinar cells (number; % total).
Table E. Individual Beta Cell Ki67 Proliferation from Tamoxifen-Treated Mixed Genetic Background (F1 C57Bl6/129) Mice. Mouse ID, β-cell (number), Ki67+ β-cells (number; % total).
Table F. Individual Physiologic Data from Tamoxifen-Treated Pure Genetic Background (129S1/SvImJ or C57BL/6J) Mice. Genetic Background, Mouse ID, sex, age prior to treatment and at harvest (months), body mass (g) at begining and end of experiment, change in body mass over treatment (g), glucose tolerance tests blood glucose measurements (mg/dl) after a 16-hour overnight fast, and at time 15, 30, 60, and 120 minutes, random fed glucose values (mg/dl) prior to treatment (day 0) and at end of treatment (day 19).
Table G. Individual Beta Cell Proliferation from Tamoxifen-Treated Pure Genetic Background (129S1/SvImJ or C57BL/6J) Mice. Mouse ID, β-cell (number), BrdU+ β-cells (number; % total).
Table H. Quantitative RT-PCR: Gene Expression Studies of Islets Harvested From Tamoxifen Treated Mixed Genetic Background (F1 C57Bl6/129) Mice. Mouse ID, cDNAs detected (cyclophillin, cyclin A2, cyclin D1,cyclin D2, cyclin D3, cyclin E1, cylin E2, p21, p27, p57, p19 Arf, p15 INK4b, p18 INK4c, menin).
(XLSX)